Balazs Albrecht
Research Subjects
Research Interests
Balazs Albrecht has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Esther Herberich
Boehringer Ingelheim Vetmedica GmbH , Ingelheim am Rhein
2 shared publications- Friederike Felicitas Rhein
Professorship of Laboratory Animal Science and Animal Welfare & Interdisciplinary Centre for Animal Welfare Research 3R (ICAR3R), Justus Liebig University Giessen, Frankfurter Str. 95, 35392 Giessen, Germany
2 shared publications - Rebecca Klee
Boehringer Ingelheim Vetmedica GmbH, Binger Straße 173, 55216 Ingelheim am Rhein, Germany
2 shared publications - Stephanie Krämer
Interdisciplinary Centre for 3Rs in Animal Research (ICAR3R), Justus-Liebig-University, 35392 Giessen, Germany
2 shared publications Carla Kroh
Boehringer Ingelheim Vetmedica GmbH , Ingelheim am Rhein
1 shared publication- Charlotte Reinhard Bjørnvad
Department of Veterinary Clinical Sciences Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
1 shared publication
Latest Publications
- Open Access
Assessment of the Awareness and Use of Quality of Life Tools in Small Animal Practices in Germany
The assessment of animal welfare and quality of life (QoL) is a critical aspect of veterinary practice. While the development of standardized tools to measure QoL has been widely discussed, there is limited research analyzing how these tools are applied in clinical practice. This study investigates the current state of QoL assessment in small animal medicine in Germany through a mixed-methods approach. A survey was conducted with veterinarians and veterinary assistants, assessing the awareness and use of QoL assessment tools in practice. In addition, interviews with veterinarians were conducted to examine their perceptions and experiences regarding the use of QoL measurement tools and the assessment of QoL itself. The findings indicate that the use of standardized QoL assessments is rare and often primarily done while doing studies. Factors hindering the widespread use of these instruments include lack of time, lack of awareness, the perceived lack of need and resistance to fitting the individuality and subjectivity of QoL into a schema. As beneficial features of such tools, veterinarians mentioned the possibility of documenting and tracking QoL and the enhancement of the relationship between professionals and clients. Further research should therefore not only focus on development but also on dissemination of such tools.
Open AccessAssessment of the Awareness and Use of Quality of Life Tools in Small Animal Practices in Germany
The assessment of animal welfare and quality of life (QoL) is a critical aspect of veterinary practice. While the development of standardized tools to measure QoL has been widely discussed, there is limited research analyzing how these tools are applied in clinical practice. This study investigates the current state of QoL assessment in small animal medicine in Germany through a mixed-methods approach. A survey was conducted with veterinarians and veterinary assistants, assessing the awareness and use of QoL assessment tools in practice. In addition, interviews with veterinarians were conducted to examine their perceptions and experiences regarding the use of QoL measurement tools and the assessment of QoL itself. The findings indicate that the use of standardized QoL assessments is rare and often primarily done while doing studies. Factors hindering the widespread use of these instruments include lack of time, lack of awareness, the perceived lack of need and resistance to fitting the individuality and subjectivity of QoL into a schema. As beneficial features of such tools, veterinarians mentioned the possibility of documenting and tracking QoL and the enhancement of the relationship between professionals and clients. Further research should therefore not only focus on development but also on dissemination of such tools.
- Open Access
Instruments to Assess Disease-Specific Quality of Life in Dogs: A Scoping Review
Quality of life (QoL) assessment has increased in veterinary medicine in recent years, as has the number of attempts to measure it. This review aimed to provide an overview and assess the quality of existing instruments measuring disease-specific QoL in dogs. The PubMed and CAB Abstracts databases were searched in February 2023 using search terms associated with dogs, well-being, and QoL to identify relevant articles which were then evaluated for information on the development and validation processes. For further analysis, 41 publications were selected, of which instruments were available for 30 publications; of these, 24 contained information on item development, while 12 of the 41 instruments described some form of instrument evaluation. Among these 12 instruments, 2 exhibited appropriate test–retest reliability, 7 exhibited acceptable internal consistency, 9 checked at least one face or content validity, and 8 tested at least one sort of hypothesis to contribute to construct validity evaluation. None of the instruments were thoroughly evaluated for all necessary psychometric aspects for their application and result interpretation. Therefore, these instruments’ usage should be carefully considered and subject to restrictions. Further research should focus on establishing guidelines aiming to achieve high standards for instrument development and validation in veterinary medicine.
Open AccessInstruments to Assess Disease-Specific Quality of Life in Dogs: A Scoping Review
Quality of life (QoL) assessment has increased in veterinary medicine in recent years, as has the number of attempts to measure it. This review aimed to provide an overview and assess the quality of existing instruments measuring disease-specific QoL in dogs. The PubMed and CAB Abstracts databases were searched in February 2023 using search terms associated with dogs, well-being, and QoL to identify relevant articles which were then evaluated for information on the development and validation processes. For further analysis, 41 publications were selected, of which instruments were available for 30 publications; of these, 24 contained information on item development, while 12 of the 41 instruments described some form of instrument evaluation. Among these 12 instruments, 2 exhibited appropriate test–retest reliability, 7 exhibited acceptable internal consistency, 9 checked at least one face or content validity, and 8 tested at least one sort of hypothesis to contribute to construct validity evaluation. None of the instruments were thoroughly evaluated for all necessary psychometric aspects for their application and result interpretation. Therefore, these instruments’ usage should be carefully considered and subject to restrictions. Further research should focus on establishing guidelines aiming to achieve high standards for instrument development and validation in veterinary medicine.
- Open Access
- 1 July 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (4) , 2099-2119
Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats
Background: Options for treatment of diabetes mellitus in cats are limited to insulin injections and monitoring for hypoglycemia. Hypothesis: Once daily sodium-glucose cotransporter-2 inhibitor velagliflozin PO is noninferior to insulin injections. Animals: Client-owned diabetic cats (127 safety; 116 efficacy assessment). Methods: Prospective, randomized (1 mg/kg velagliflozin), positive controlled (titrated Caninsulin), open label, noninferiority field trial, comparing number of cats with treatment success in ≥1 clinical variable and ≥1 glycemic variable (margin Δ: 15%) on Day 45; secondary endpoints included glycemic and clinical assessments during 91 days. Results: On Day 45, 29/54 (54%) velagliflozin-treated cats and 26/62 (42%) Caninsulin-treated cats showed treatment success, demonstrating noninferiority (difference −11.8%; upper 1-sided 97.5% confidence interval, −∞ to 6.3%). By Day 91, quality of life (QoL), polyuria, and polydipsia had improved in 81%, 54% and 61% (velagliflozin); on blood glucose (BG) curves, mean BG was <252 mg/dL in 42/54 (78%; velagliflozin) and 37/62 (60%; Caninsulin); minimum BG was <162 mg/dL in 41/54 (76%; velagliflozin) and 41/62 (66%; Caninsulin); serum fructosamine was <450 μmol/L in 41/54 (76%; velagliflozin) and 38/62 (61%; Caninsulin). Velagliflozin's most frequent adverse events were loose feces/diarrhea (n = 23/61, 38%), positive urine culture (n = 19/61, 31%), and nonclinical hypoglycemia (BG <63 mg/dL; n = 8/61, 13%); Caninsulin's: clinical and nonclinical hypoglycemia (n = 35/66, 53%), positive urine culture (n = 18/66, 27%), and loose feces/diarrhea (n = 10/66, 15%). Diabetic ketoacidosis occurred in 4/61 (7%; velagliflozin) and 0/66 (Caninsulin). Conclusions and Clinical Importance: Once daily oral administration of velagliflozin was noninferior to insulin injections, showed good QoL and glycemia without clinical hypoglycemia.
- 1 July 2024
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 38 (4) , 2099-2119
Open AccessEfficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats
Background: Options for treatment of diabetes mellitus in cats are limited to insulin injections and monitoring for hypoglycemia. Hypothesis: Once daily sodium-glucose cotransporter-2 inhibitor velagliflozin PO is noninferior to insulin injections. Animals: Client-owned diabetic cats (127 safety; 116 efficacy assessment). Methods: Prospective, randomized (1 mg/kg velagliflozin), positive controlled (titrated Caninsulin), open label, noninferiority field trial, comparing number of cats with treatment success in ≥1 clinical variable and ≥1 glycemic variable (margin Δ: 15%) on Day 45; secondary endpoints included glycemic and clinical assessments during 91 days. Results: On Day 45, 29/54 (54%) velagliflozin-treated cats and 26/62 (42%) Caninsulin-treated cats showed treatment success, demonstrating noninferiority (difference −11.8%; upper 1-sided 97.5% confidence interval, −∞ to 6.3%). By Day 91, quality of life (QoL), polyuria, and polydipsia had improved in 81%, 54% and 61% (velagliflozin); on blood glucose (BG) curves, mean BG was <252 mg/dL in 42/54 (78%; velagliflozin) and 37/62 (60%; Caninsulin); minimum BG was <162 mg/dL in 41/54 (76%; velagliflozin) and 41/62 (66%; Caninsulin); serum fructosamine was <450 μmol/L in 41/54 (76%; velagliflozin) and 38/62 (61%; Caninsulin). Velagliflozin's most frequent adverse events were loose feces/diarrhea (n = 23/61, 38%), positive urine culture (n = 19/61, 31%), and nonclinical hypoglycemia (BG <63 mg/dL; n = 8/61, 13%); Caninsulin's: clinical and nonclinical hypoglycemia (n = 35/66, 53%), positive urine culture (n = 18/66, 27%), and loose feces/diarrhea (n = 10/66, 15%). Diabetic ketoacidosis occurred in 4/61 (7%; velagliflozin) and 0/66 (Caninsulin). Conclusions and Clinical Importance: Once daily oral administration of velagliflozin was noninferior to insulin injections, showed good QoL and glycemia without clinical hypoglycemia.
- Open Access
- 18 December 2018
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 33 (2) , 413-422
Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial
Background Efficacy of telmisartan in treating hypertension (HT) in cats has not been largely investigated. Objective Telmisartan oral solution effectively controls systolic arterial blood pressure (SABP) in hypertensive cats. Animals Two-hundred eighty-five client-owned cats with systemic HT. Methods Prospective, multicenter, placebo-controlled, randomized, double-blinded study. Hypertensive cats diagnosed with SABP ≥160 mmHg and ≤200 mmHg without target-organ-damage were randomized (2 : 1 ratio) to receive 2 mg/kg telmisartan or placebo q24 PO. A 28-day efficacy phase was followed by a 120-day extended use phase. Efficacy was defined as significant difference in mean SABP reduction between telmisartan and placebo on Day 14 and group mean reduction in SABP of > 20 mmHg by telmisartan on Day 28 compared to baseline. Results Two-hundred fifty-two cats completed the efficacy and 144 cats the extended use phases. Mean SABP reduction at Day 14 differed significantly between groups (P < .001). Telmisartan reduced baseline SABP of 179 mmHg by 19.2 (95% confidence interval [CI]: 15.92-22.52) and 24.6 (95% CI: 21.11-28.14) mmHg at Days 14 and 28. The placebo group baseline SABP of 177 mmHg was reduced by 9.0 (95% CI: 5.30-12.80) and 11.4 (95% CI: 7.94-14.95) mmHg, respectively. Of note, 52% of telmisartan-treated cats had SABP <150 mmHg at Day 28. Mean SABP reduction by telmisartan in severe (≥180 mmHg) and moderate HT (160-179 mmHg) was comparable and persistent over time. Conclusions and Clinical Importance Telmisartan solution (PO) was effective in reducing SABP in hypertensive cats with SABP ≥160 mmHg and ≤200 mmHg.
- 18 December 2018
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 33 (2) , 413-422
Open AccessEfficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial
Background Efficacy of telmisartan in treating hypertension (HT) in cats has not been largely investigated. Objective Telmisartan oral solution effectively controls systolic arterial blood pressure (SABP) in hypertensive cats. Animals Two-hundred eighty-five client-owned cats with systemic HT. Methods Prospective, multicenter, placebo-controlled, randomized, double-blinded study. Hypertensive cats diagnosed with SABP ≥160 mmHg and ≤200 mmHg without target-organ-damage were randomized (2 : 1 ratio) to receive 2 mg/kg telmisartan or placebo q24 PO. A 28-day efficacy phase was followed by a 120-day extended use phase. Efficacy was defined as significant difference in mean SABP reduction between telmisartan and placebo on Day 14 and group mean reduction in SABP of > 20 mmHg by telmisartan on Day 28 compared to baseline. Results Two-hundred fifty-two cats completed the efficacy and 144 cats the extended use phases. Mean SABP reduction at Day 14 differed significantly between groups (P < .001). Telmisartan reduced baseline SABP of 179 mmHg by 19.2 (95% confidence interval [CI]: 15.92-22.52) and 24.6 (95% CI: 21.11-28.14) mmHg at Days 14 and 28. The placebo group baseline SABP of 177 mmHg was reduced by 9.0 (95% CI: 5.30-12.80) and 11.4 (95% CI: 7.94-14.95) mmHg, respectively. Of note, 52% of telmisartan-treated cats had SABP <150 mmHg at Day 28. Mean SABP reduction by telmisartan in severe (≥180 mmHg) and moderate HT (160-179 mmHg) was comparable and persistent over time. Conclusions and Clinical Importance Telmisartan solution (PO) was effective in reducing SABP in hypertensive cats with SABP ≥160 mmHg and ≤200 mmHg.